PROCESS FOR MEDICAMENTOUS CORRECTION OF MICROINFLAMMATION ASSOCIATED WITH INSULIN RESISTANCE IN PATIENTS WITH ARTERIAL HYPERTENSION

摘要

A process for the medicamentous correction of microinflammation associated with insulin resistance in the patients with the arterial hypertension provides for assaying TNF-α and C-RP in the blood. When TNF-α exceeds 6.7 pg/mL and C-RP exceeds 1.9 mg/L, Lerkanidipin, Candesartan, Atorvastatin and Metformin are provided for 2 months at the therapeutically effective doses.